Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar 4;15(1):35.
doi: 10.1186/s13098-023-00998-y.

Potential clinical biomarkers and perspectives in diabetic cardiomyopathy

Jianxin Deng #  1 , Fang Yan #  2 , Jinglun Tian  3 , Aijun Qiao  4   5 , Dewen Yan  6
Affiliations
Review

Potential clinical biomarkers and perspectives in diabetic cardiomyopathy

Jianxin Deng et al. Diabetol Metab Syndr. .

Abstract

Diabetic cardiomyopathy (DCM) is a serious cardiovascular complication and the leading cause of death in diabetic patients. Patients typically do not experience any symptoms and have normal systolic and diastolic cardiac functions in the early stages of DCM. Because the majority of cardiac tissue has already been destroyed by the time DCM is detected, research must be conducted on biomarkers for early DCM, early diagnosis of DCM patients, and early symptomatic management to minimize mortality rates among DCM patients. Most of the existing implemented clinical markers are not very specific for DCM, especially in the early stages of DCM. Recent studies have shown that a number of new novel markers, such as galactin-3 (Gal-3), adiponectin (APN), and irisin, have significant changes in the clinical course of the various stages of DCM, suggesting that we may have a positive effect on the identification of DCM. As a summary of the current state of knowledge regarding DCM biomarkers, this review aims to inspire new ideas for identifying clinical markers and related pathophysiologic mechanisms that could be used in the early diagnosis and treatment of DCM.

Keywords: Apelin; Biomarkers; Diabetic cardiomyopathy; Galactin-3; Irisin; NLRP3 inflammasome.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing of interests.

Figures

Fig. 1
Fig. 1
Diabetic cardiomyopathy pathophysiological mechanisms
See this image and copyright information in PMC

References

    1. IDF Diabetes Atlas 10th edition. 2021.
    1. Gulsin GS, Athithan L, McCann GP. Diabetic cardiomyopathy: prevalence, determinants and potential treatments. Ther Adv Endocrinol Metab. 2019;10:2042018819834869. doi: 10.1177/2042018819834869. - DOI - PMC - PubMed
    1. Paulus WJ, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007;28:2539–2550. doi: 10.1093/eurheartj/ehm037. - DOI - PubMed
    1. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974;34:29–34. doi: 10.1016/0002-9149(74)90089-7. - DOI - PubMed
    1. Thrainsdottir IS, Aspelund T, Thorgeirsson G, Gudnason V, Hardarson T, Malmberg K, et al. The association between glucose abnormalities and heart failure in the population-based Reykjavik study. Diabetes Care. 2005;28:612–616. doi: 10.2337/diacare.28.3.612. - DOI - PubMed